Biopharma company Jazz Pharmaceuticals (NASDAQ: JAZZ) will be reporting results this Tuesday after market hours. Here’s what you need to know.
Jazz Pharmaceuticals beat analysts’ revenue expectations last quarter, reporting revenues of $1.20 billion, up 10.1% year on year. It was a slower quarter for the company, with full-year revenue guidance missing analysts’ expectations.
Is Jazz Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Jazz Pharmaceuticals’s revenue to grow 8.8% year on year, improving from its flat revenue in the same quarter last year.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Jazz Pharmaceuticals has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Jazz Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 55.5%, beating analysts’ expectations by 13.7%, and Merck reported revenues up 4.9%, topping estimates by 3%. Eli Lilly traded up 13.2% following the results while Merck was also up 1%.
Read our full analysis of Eli Lilly’s results here and Merck’s results here.
There has been positive sentiment among investors in the pharmaceuticals segment, with share prices up 6% on average over the last month. Jazz Pharmaceuticals is up 9.7% during the same time and is heading into earnings with an average analyst price target of $226.12 (compared to the current share price of $205).
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
